|
1
|
Buchsbaum DJ and Croce CM: Will detection
of microRNA biomarkers in blood improve the diagnosis and survival
of patients with pancreatic cancer? JAMA. 311:363–365. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kohler BA, Ward E, McCarthy BJ, Schymura
MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA and Edwards
BK: Annual report to the nation on the status of cancer, 1975–2007,
featuring tumors of the brain and other nervous system. J Natl
Cancer Inst. 103:714–736. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Castro SM, Biere SS, Lagarde SM, Busch
OR, van Gulik TM and Gouma DJ: Validation of a nomogram for
predicting survival after resection for adenocarcinoma of the
pancreas. Br J Surg. 96:417–423. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Slater E, Amrillaeva V, Fendrich V,
Bartsch D, Earl J, Vitone LJ, Neoptolemos JP and Greenhalf W:
Palladin mutation causes familial pancreatic cancer: Absence in
European families. PLoS Med. 4:e1642007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Höckel M and Vaupel P: Tumor hypoxia:
Definitions and current clinical, biologic, and molecular aspects.
J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Patot MC and Gassmann M: Hypoxia:
Adapting to high altitude by mutating EPAS-1, the gene encoding
HIF-2α. High Alt Med Biol. 12:157–167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chavez JC, Baranova O, Lin J and Pichiule
P: The transcriptional activator hypoxia inducible factor 2
(HIF-2/EPAS-1) regulates the oxygen-dependent expression of
erythropoietin in cortical astrocytes. J Neurosci. 26:9471–9481.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wolff M, Jelkmann W, Dunst J and Depping
R: The Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT/HIF-1β)
is influenced by hypoxia and hypoxia-mimetics. Cell Physiol
Biochem. 32:849–858. 2013. View Article : Google Scholar
|
|
9
|
Glover LE, Bowers BE, Saeedi B, et al:
Control of creatine metabolism by HIF is an endogenous mechanism of
barrier regulation in colitis. Proc Natl Acad Sci USA.
110:19820–19825. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahn YT, Chua MS, Whitlock JP Jr, Shin YC,
Song WH, Kim Y, Eom CY and An WG: Rodent-specific hypoxia response
elements enhance PAI-1 expression through HIF-1 or HIF-2 in mouse
hepatoma cells. Int J Oncol. 37:1627–1638. 2010.PubMed/NCBI
|
|
11
|
Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang
GF and Jing S: Prognostic significance of HIF-2alpha/EPAS1
expression in hepatocellular carcinoma. World J Gastroenterol.
13:3176–3182. 2007.PubMed/NCBI
|
|
12
|
Baba Y, Nosho K, Shima K, Irahara N, Chan
AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS and Ogino S:
HIF1A overexpression is associated with poor prognosis in a cohort
of 731 colorectal cancers. Am J Pathol. 176:2292–2301. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bangoura G, Yang LY, Huang GW and Wang W:
Expression of HIF-2alpha/EPAS1 in hepatocellular carcinoma. World J
Gastroenterol. 10:525–530. 2004.PubMed/NCBI
|
|
14
|
Pirollo KF, Rait A, Zhou Q, Hwang SH,
Dagata JA, Zon G, Hogrefe RI, Palchik G and Chang EH: Materializing
the potential of small interfering RNA via a tumor-targeting
nanodelivery system. Cancer Res. 67:2938–2943. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Campolongo MJ and Luo D: Drug delivery:
Old polymer learns new tracts. Nat Mater. 8:447–448. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Costantino L, Gandolfi F, Bossy-Nobs L,
Tosi G, Gurny R, Rivasi F, Vandelli MA and Forni F: Nanoparticulate
drug carriers based on hybrid
poly(D,L-lactide-co-glycolide)-dendron structures. Biomaterials.
27:4635–4645. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Das J, Das S, Paul A, Samadder A,
Bhattacharyya SS and Khuda-Bukhsh AR: Assessment of drug delivery
and anticancer potentials of nanoparticles-loaded siRNA targeting
STAT3 in lung cancer, in vitro and in vivo. Toxicol Lett.
225:454–466. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng L, Li J, Wang Y, et al: Combination
of siRNA-directed Kras oncogene silencing and arsenic-induced
apoptosis using a nanomedicine strategy for the effective treatment
of pancreatic cancer. Nanomedicine. 10:463–472. 2014. View Article : Google Scholar
|
|
19
|
Xu J, Singh A and Amiji MM:
Redox-responsive targeted gelatin nanoparticles for delivery of
combination wt-p53 expressing plasmid DNA and gemcitabine in the
treatment of pancreatic cancer. BMC Cancer. 14:752014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pittella F, Miyata K, Maeda Y, Suma T,
Watanabe S, Chen Q, Christie RJ, Osada K, Nishiyama N and Kataoka
K: Pancreatic cancer therapy by systemic administration of VEGF
siRNA contained in calcium phosphate/charge-conversional polymer
hybrid nanoparticles. J Control Release. 161:868–874. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chae JM, Mo SM and Oh IJ: Effects of
poloxamer 188 on the characteristics of poly(lactide-co-glycolide)
nanoparticles. J Nanosci Nanotechnol. 10:3224–3227. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan F, Zhang C, Zheng Y, Mei L, Tang L,
Song C, Sun H and Huang L: The effect of poloxamer 188 on
nanoparticle morphology, size, cancer cell uptake, and
cytotoxicity. Nanomedicine. 6:170–178. 2010. View Article : Google Scholar
|
|
23
|
Lai JY and Ma DH: Glutaraldehyde
cross-linking of amniotic membranes affects their nanofibrous
structures and limbal epithelial cell culture characteristics. Int
J Nanomedicine. 8:4157–4168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pett-Ridge J and Weber PK: NanoSIP:
NanoSIMS applications for microbial biology. Methods Mol Biol.
881:375–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ji XT, Huang L and Huang HQ: Construction
of nanometer cisplatin core-ferritin (NCC-F) and proteomic analysis
of gastric cancer cell apoptosis induced with cisplatin released
from the NCC-F. J Proteomics. 75:3145–3157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim DH and Rossi JJ: Strategies for
silencing human disease using RNA interference. Nat Rev Genet.
8:173–184. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thomlinson RH and Gray LH: The
histological structure of some human lung cancers and the possible
implications for radiotherapy. Br J Cancer. 9:539–549. 1955.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harada H: How can we overcome tumor
hypoxia in radiation therapy? J Radiat Res. 52:545–556. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Moeller BJ, Dreher MR, Rabbani ZN,
Schroeder T, Cao Y, Li CY and Dewhirst MW: Pleiotropic effects of
HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 8:99–110.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pugh CW and Ratcliffe PJ: Regulation of
angiogenesis by hypoxia: Role of the HIF system. Nat Med.
9:677–684. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Manalo DJ, Rowan A, Lavoie T, Natarajan L,
Kelly BD, Ye SQ, Garcia JG and Semenza GL: Transcriptional
regulation of vascular endothelial cell responses to hypoxia by
HIF-1. Blood. 105:659–669. 2005. View Article : Google Scholar
|
|
32
|
Arias-Pulido H, Chaher N, Gong Y, Qualls
C, Vargas J and Royce M: Tumor stromal vascular endothelial growth
factor A is predictive of poor outcome in inflammatory breast
cancer. BMC Cancer. 12:2982012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu L, Deng L, Li J, Zhang Y and Hu L: The
prognostic value of vascular endothelial growth factor in ovarian
cancer: A systematic review and meta-analysis. Gynecol Oncol.
128:391–396. 2013. View Article : Google Scholar
|
